Liver fibrosis treatment sales will rise through 2036, driven by PPAR-Alpha agonists at 35.2% of the treatment type segment in 2026. The market was valued at USD 20.28 billion in 2025 and is expected to be worth USD 65.19 billion by 2036, creating an incremental opportunity of USD 42.64 billion.